Pendopharm signs sponsorship with CFL
Montreal-based pharmaceutical company Pendopharm has signed a three-year sponsorship agreement with the Canadian Football League. Through this agreement, the company will provide the teams of the league with its Monovisc knee-joint pain relief product. The company will also use the exposure to raise awareness of the product among consumers, as well as the condition of osteoarthritis. This exposure will include broadcast, in-stadium and online elements, including during the Grey Cup championship game. Pendopharm is a division of Pharmascience.
"This partnership with the Canadian Football League is a first for us at Pendopharm and we are looking forward to building a strong bond and a long-lasting relationship between both organizations," said François David, senior marketing director at Pendopharm. "Our diverse portfolio of brands is built to address the specific needs of both patients and healthcare professionals. Monovisc is the perfect example of this, with a product profile aligned perfectly with the need for a viscosupplementation treatment of choice for professional and former athletes, Canadian consumers, or those suffering from a previous injury."